

1 **Bacterial multicellular behavior in antiviral defense**

2

3 Tom Luthe<sup>1</sup>, Larissa Kever<sup>1</sup>, Kai Thormann<sup>2</sup>, and Julia Frunzke<sup>1\*</sup>

4

5 <sup>1</sup>) Institute of Bio- und Geosciences, IBG-1: Biotechnology, Forschungszentrum Jülich, 52425  
6 Jülich, Germany

7 <sup>2</sup>) Institute of Microbiology and Molecular Biology, Justus-Liebig University Gießen, 35392  
8 Gießen, Germany

9

10

11 \*Corresponding author:

12 Julia Frunzke; Email: [j.frunzke@fz-juelich.de](mailto:j.frunzke@fz-juelich.de); Phone: +49 2461 615430

13

14 Keywords: bacteriophages, phage-host interaction, chemical defense, quorum sensing,  
15 membrane vesicles, biofilms

16

## 17 **Highlights**

- 18 - Bacterial multicellular behaviour plays an important role in predatory interactions
- 19 - Small molecules involved in signalling or chemical defense contribute to phage defense
- 20 - Membrane vesicles can act as phage decoys
- 21 - Biofilm matrix is an important barrier against phages

22

## 23 **Abstract**

24 Multicellular behaviour benefits seemingly simple organisms such as bacteria, by improving nutrient  
25 uptake, resistance to stresses or by providing advantages in predatory interactions. Several recent  
26 studies have shown that this also extends to the defense against bacteriophages, which are  
27 omnipresent in almost all habitats. In this review, we summarize strategies conferring protection  
28 against phage infection at the multicellular level, covering secretion of small antiphage molecules or  
29 membrane vesicles, the role of quorum sensing in phage defense, and the impact of biofilm  
30 components and architecture. Recent studies focusing on these topics push the boundaries of our  
31 understanding of the bacterial immune system and set the ground for an appreciation of bacterial  
32 multicellular behaviour in antiviral defense.

33

## 34 **Introduction**

35 *"All for one and one for all, united we stand divided we fall."* Alexandre Dumas, The Three Musketeers

36 Viruses infecting bacteria, so-called bacteriophages, represent the most abundant predator on this  
37 planet, shaping life in almost all ecosystems. The ongoing 'arms race' between phages and bacteria  
38 has led to the evolution of diverse antiphage strategies collectively referred to as the bacterial 'immune  
39 system' [1,2]. Classical examples are restriction-modification (RM), CRISPR-Cas and abortive infection  
40 encoded by a large fraction of bacterial genomes. Currently, we are experiencing an unprecedented  
41 expansion of our understanding of bacterial antiviral immunity driven by the identification of  
42 numerous new antiphage systems – several of which are hinting towards a prokaryotic origin of human  
43 cell-autonomous innate immune mechanisms [3,4]. These ground-breaking discoveries were made  
44 possible by the finding that antiviral systems often co-localize in so-called 'defense islands' in  
45 prokaryotic genomes and by intensive screenings based on functional selection [5-8].

46 Effective antiviral defense of a single bacterial cell also protects the entire population, as it stops the  
47 spread of infection and prevents the release of new phages. Most of the systems described recently

48 function at the intracellular level by targeting phage nucleic acids or by triggering death of the infected  
49 cell. However, several studies reported on bacterial antiphage strategies, which are shared by cells in  
50 a community and therefore can potentially be considered as antiviral public goods.

51 In natural environments, microbial communities typically show a high order of organization and  
52 emergent properties of bacterial multicellularity. The advantages of multicellular behaviour are  
53 numerous and include the improved acquisition of nutrients, resistance to physical stresses or  
54 antimicrobial molecules, and the protection from predators [9]. In this short review, we will move  
55 towards the appreciation of bacterial multicellular behaviour in antiviral defense. These mechanisms  
56 include the production and secretion of antiphage small molecules, membrane vesicles, quorum  
57 sensing-based activation of defense systems and the impact of biofilm architecture.

58

## 59 **Quorum sensing**

60 The concept of quorum sensing (QS) is at the heart of bacterial multicellularity as it defines the ability  
61 of bacterial populations to make group decisions. This communication between cells is mediated via  
62 the production and recognition of small molecules, so-called autoinducers, which can affect bacterial  
63 behavior associated with virulence, biofilm formation, horizontal gene transfer, and bioluminescence  
64 [10,11]. Several studies clearly show that QS also has an effect on the susceptibility of bacteria towards  
65 phage infection and on the coordination of phage defense strategies.

66 In presence of the autoinducers AHL, CAI-1 or AI-2, phage adsorption was shown to be reduced for  
67 *Escherichia coli* phages  $\lambda$  and  $\chi$ , as well as different *Vibrio* phages by downregulation of the respective  
68 receptor genes [12-14]. Communication via QS also led to the inactivation of phages via the production  
69 of hemagglutinin protease in *Vibrio cholerae* [12]. QS was further shown to affect the adaptive  
70 immunity of CRISPR-Cas by activating *cas* gene expression in *Pseudomonas aeruginosa* and a  
71 *Serratia sp.* [15,16]. Moreover, QS peptides from different species triggered abortive infection in *E. coli*  
72 through the *mazEF* toxin-antitoxin module, which was shown to inhibit the spread of phage P1 [17,18].  
73 Besides this direct impact on phage defense, the influence of QS on phage susceptibility can also be  
74 indirect via the downregulation of metabolic activity affecting phage infection [19,20].

75 Considering the diverse effects of QS on bacterial antiviral defense, it is not surprising that phages also  
76 eavesdrop on the communication of their host to optimize their infection strategy [11,21,22] or to  
77 disrupt key biological pathways [23].

78

## 79 **Chemical defense**

80 Besides the exchange of information, small molecules produced by bacteria can also have themselves  
81 antiphage properties as recently described for compounds belonging to the classes of anthracyclines  
82 and aminoglycosides. Environmental bacteria, especially members of the genus of *Streptomyces*, are  
83 prolific producers of bioactive compounds, which are known to provide important fitness advantages  
84 in competitive, cooperative as well as predatory interactions [24]. Inhibition of phage infection by  
85 bacterial small molecules received first attention in the 1950s and 1960s with a special emphasis on  
86 the identification of antiphage molecules applicable in agricultural and medical sectors as summarized  
87 in a recent review article [25]. It is, however, striking that their potential role in the protection against  
88 the most abundant predator in the environment – viruses – remained a major blind spot.

89 Recently, DNA-intercalating molecules belonging to the class of anthracyclines were shown to inhibit  
90 infection of several dsDNA phages infecting *Streptomyces coelicolor*, *Escherichia coli* or *Pseudomonas*

91 *aeruginosa* [26]. Anthracyclines are naturally produced by *Streptomyces* and are among the most  
92 efficient anticancer agents used in clinics [27]. Mechanistically, these compounds were proposed to  
93 interfere with phage infection at an early step of the phage life cycle, namely between DNA injection  
94 and replication [26].

95 A second class of antibiotics, which recently gained interest in the context of phage defense are  
96 aminoglycosides [28]. Like anthracyclines, aminoglycosides are mainly produced by *Streptomyces*.  
97 These bactericidal, polycationic antibiotics act by targeting the 16S rRNA of the 30S ribosomal subunit,  
98 thereby interfering with bacterial protein translation [29]. Inhibition of phages by these compounds  
99 was observed for disparate dsDNA phages infecting Gram-positive and Gram-negative bacterial hosts.

100 It is striking that several – if not most – of the previously described antiphage compounds produced by  
101 bacteria have antibacterial properties, too. In nature, producers of antimicrobial molecules typically  
102 express a sophisticated set of self-resistance mechanisms [30,31]. This needs to be considered to allow  
103 the appreciation of potential antiviral effects of the respective molecule. First insights gained for  
104 aminoglycosides suggests that the molecular targets for inhibition of bacteria and phages are distinct.  
105 Acetylation of the aminoglycoside antibiotic apramycin abolished the antibacterial activity of the  
106 compound, but did not affect its antiphage properties [32].

107 The ecological relevance of chemical defense mediated antiphage defense by small molecules is  
108 supported by the inhibitory effect of culture supernatants of natural producer strains when added to  
109 phage infection experiments [26,32]. Accordingly, with their excretion into the environment and their  
110 broad-spectrum activity, these secondary metabolites – dependent on locally achieved concentrations  
111 – could provide a chemical defense against phages at the community level by creating an antiviral  
112 milieu. However, resistance to the antibacterial effect of the molecule(s) is prerequisite to be able to  
113 benefit from the antiviral properties of the respective molecule.

114 Apart from a direct interference of bacterial small molecules with phage infection, bacteriostatic  
115 protein translation inhibitors can also provide protection against phage infection by increasing the  
116 efficiency of CRISPR-Cas immunity. This can be achieved either by decelerating phage reproduction,  
117 which extends the time for the acquisition of adaptive CRISPR immunity [33], or by interfering with the  
118 production of phage-encoded anti-CRISPR proteins [34].

119 Notably, production of secondary metabolites is intricately linked to *Streptomyces* development. Just  
120 recently, Luthe and colleagues showed the importance of cellular development for the emergence of  
121 transient phage resistance overall highlighting the complexity of multicellular antiphage defense  
122 employed by *Streptomyces* (Luthe et al, in revision).

123

124 **Membrane Vesicles**

125 Another protective shield has been shown to be provided by the secretion of membrane vesicles  
126 (MVs), which are generated by all living cells. As components of the extracellular space, membrane  
127 vesicles affect intercellular interaction in manifold ways including DNA transfer, metabolite export,  
128 virulence and cell-cell communication. Although the most extensively studied membrane vesicles are  
129 derived from the outer membrane of gram-negative bacteria, there are different routes and triggers  
130 of membrane vesicle formation in both Gram-negative and –positive cells [35,36].

131 Several recent studies revealed that MVs may protect from viral predation by acting as phage decoys  
132 leading to adsorption of phages and resulting in less productive phage infections of the population [37-  
133 41]. Phage-induced lysis of bacterial cells is supposed to contribute extensively to the formation of  
134 membrane vesicles in nature [42]. This raises the possibility that membrane vesicles may serve as a  
135 defense mechanism by transporting signaling molecules such as quorum sensing molecules in a  
136 concentrated manner, as has been observed in *Paracoccus denitrificans* [43,44]. This could help  
137 bacteria communicate and coordinate their defense against phages more effectively. Further research  
138 is needed to understand the exact role of membrane vesicles in bacterial antiviral defense.

139

140 **Biofilms**

141 Among the huge body of studies that have addressed the interaction of phages with their hosts, most  
142 of the data – in particular studies on molecular mechanisms underlying the phage-host tug-of-war –  
143 stems from planktonic cultures, where diffusing phages have more or less free access to their prey  
144 cells. However, in most environments the majority of bacteria exists in biofilms, where the bacteria  
145 are physically associated with each other in a self-produced matrix engulfing the community [45-47].  
146 This results in a number of inherent properties of the biofilm community that drastically increases the  
147 tolerance of the bacterial populations against all kinds of environmental stresses. It has been observed  
148 that, most times, the inherent recalcitrance of cells in biofilms also extends to phage predation.

149 Intuitively, a local accumulation of potential prey cells may seem beneficial for phage predation,  
150 however, the prey clustering is likely to result in increased co-infections causing a drop in phage  
151 progeny per cell [48]. In addition, all biofilm communities are characterized by a pronounced metabolic  
152 stratification due to different access to metabolites including oxygen. Thus, many cells within the  
153 community exhibit a reduced metabolic activity up to the point of dormancy [49]. Although there are  
154 some phages that are able to infect and lyse dormant cells, many if not most phages do not proliferate  
155 efficiently at low metabolic activity of the host cells [50-53]. Such dormant, dead or phage-resistant  
156 cells may still efficiently bind phage particles and thus serve as potent phage absorbers or a shield that

157 protect their susceptible counterparts [54-60]. In addition, as elaborated above, outer membrane  
158 vesicles (OMVs) produced by many bacteria are present within biofilms and act as additional decoys  
159 for phage predation.

160 Another important factor that governs phage-biofilm interactions is the biofilm matrix, which is  
161 encasing the bacterial cells and commonly consists of various polymeric substances such as  
162 exopolysaccharides, various proteins, nucleic acids and lipids [46]. Intuitively and as predicted by a  
163 biofilm simulation network [61], the interaction of phages and bacteria depends on the ability of the  
164 rather large phage particles to diffuse through the biofilm and, thus, to a significant part on the  
165 interaction of phages with the matrix. Correspondingly, several studies demonstrate that the biofilm  
166 matrix limits phage diffusion and viral predation of the cells [62-66]. The exopolysaccharide stewartan  
167 showed concentration-dependent limiting of phage diffusion, unless the phages were decorated with  
168 corresponding depolymerases [67]. Another study showed that active phages are captured by  
169 extracellular proteinaceous assemblages referred to as curli. Notably, the tight binding of phages by  
170 these structures implicates that matrix components may have evolved to efficiently absorb specific  
171 intruding phages [68]. Phages can thus be efficiently retained in the biofilm, and it has been shown  
172 that this not only prevents the embedded cells from phage contact and infection but may also turn the  
173 captured phages into a protective barrier against other susceptible invading or evading bacteria [68-  
174 70].

175 Taken together, cells in biofilms are generally more recalcitrant towards phage assaults. This can  
176 mainly be attributed to the biofilm structure and the resulting spatial and metabolic stratification,  
177 which in concert limit access to the prey cells and successful phage proliferation. The studies implicate  
178 that, as a whole, a biofilm community is a reservoir of a multitude of phage-host interactions, which  
179 we are only beginning to understand [71,72].

180

### 181 **Conclusions and future perspectives**

182 The recent discovery of numerous new systems impressively demonstrates the gaps in our  
183 understanding of the bacterial immune system [1,3]. In this short review, we summarize systems  
184 conferring protection at the multicellular level by the secretion of small molecules, membrane vesicles  
185 or via components of the biofilm matrix. In the past, antiviral defense has been mainly studied at the  
186 level of isolated systems. It is, however, the interaction between different lines of defense, which  
187 ultimately shapes the immune system – a notion which is well accepted for antiviral immunity in  
188 eukaryotes, but still very underdeveloped for the prokaryotic world. Technological advances now  
189 enable the spatiotemporal analysis of the interaction and complementation of different antiviral  
190 systems providing unprecedented insights into their interaction and interdependencies within  
191 bacterial species [73,74].

192 The majority of microbial interactions take place in spatially structured environments. Consequently,  
193 several factors, like the physiological status of neighbouring cells and the structure and individual  
194 components of the biofilm, have important implications for the range of microbial interactions. Several  
195 recent studies reveal the predominance of short-range interactions in densely packed bacterial  
196 communities and the impact of system architecture and cell permeability on spatial scales [75,76].  
197 Consequently, these factors likely also shape the dimensions of antiviral defense provided through the  
198 secretion of small molecules or membrane vesicles.

199 The spatiotemporal analysis of antiviral defense at the multicellular level will also allow to study the  
200 response of bacterial populations to viral infection and represents a powerful approach for the  
201 identification of new multicellular strategies involved in the communication between cells or division  
202 of labor through genetic and/or phenotypic diversification. Genomic diversification has recently been  
203 shown for *Streptomyces* colonies leading to the emergence of hyperproducers of antimicrobial  
204 substances [77]. After their emergence, the fraction of genetically degenerated hyperproducers was  
205 shown to undergo further mutational meltdown leading to their removal from the population [78] – a  
206 concept which is reminiscent to altruism expressed by sterile castes in social insects.

207 These recent examples provide first insights into the multiple dimensions of bacterial multicellular  
208 behaviour and its relevance for antiviral defense. Combining molecular mechanistic, evolutionary, and  
209 ecological approaches is now essential for a comprehensive understanding of the ecological relevance  
210 of these systems in the context of microbial interaction.

211

212

### 213 **Acknowledgements**

214 Research in the Frunzke Lab is supported by the European Research Council (ERC Starting Grant  
215 757563) and the Deutsche Forschungsgemeinschaft (SPP 2330, project 464434020). The Thormann  
216 Lab is supported by the Deutsche Forschungsgemeinschaft (SPP2330, TH831/10-1).

217

218

219

220



221 **References**

- 222 1. Bernheim A, Sorek R: **The pan-immune system of bacteria: antiviral defence as a community**  
223 **resource**. *Nat Rev Microbiol* 2020, **18**:113-119.
- 224 2. Hampton HG, Watson BNJ, Fineran PC: **The arms race between bacteria and their phage foes**.  
225 *Nature* 2020, **577**:327-336.
- 226 3. Tal N, Sorek R: **SnapShot: Bacterial immunity**. *Cell* 2022, **185**:578-578.e571.
- 227 4. Wein T, Sorek R: **Bacterial origins of human cell-autonomous innate immune mechanisms**. *Nat Rev*  
228 *Immunol* 2022, **22**:629-638.
- 229 5. Doron S, Melamed S, Ofir G, Leavitt A, Lopatina A, Keren M, Amitai G, Sorek R: **Systematic discovery**  
230 **of antiphage defense systems in the microbial pangenome**. *Science* 2018, **359**.
- 231 6. Gao L, Altae-Tran H, Böhning F, Makarova KS, Segel M, Schmid-Burgk JL, Koob J, Wolf YI, Koonin EV,  
232 Zhang F: **Diverse enzymatic activities mediate antiviral immunity in prokaryotes**. *Science*  
233 2020, **369**:1077-1084.
- 234 7. Vassallo CN, Doering CR, Littlehale ML, Teodoro GIC, Laub MT: **A functional selection reveals**  
235 **previously undetected anti-phage defence systems in the *E. coli* pangenome**. *Nat Microbiol*  
236 2022, **7**:1568-1579.
- 237 8. Millman A, Melamed S, Leavitt A, Doron S, Bernheim A, Hör J, Garb J, Bechon N, Brandis A, Lopatina  
238 A, et al.: **An expanded arsenal of immune systems that protect bacteria from phages**. *Cell*  
239 *Host Microbe* 2022.
- 240 9. Lyons NA, Kolter R: **On the evolution of bacterial multicellularity**. *Curr Opin Microbiol* 2015, **24**:21-  
241 28.
- 242 10. Abisado RG, Benomar S, Klaus JR, Dandekar AA, Chandler JR: **Bacterial Quorum Sensing and**  
243 **Microbial Community Interactions**. *mBio* 2018, **9**.
- 244 11. Duddy OP, Bassler BL: **Quorum sensing across bacterial and viral domains**. *PLoS Pathog* 2021,  
245 **17**:e1009074.
- 246 12. Hoque MM, Naser IB, Bari SM, Zhu J, Mekalanos JJ, Faruque SM: **Quorum Regulated Resistance of**  
247 ***Vibrio cholerae* against Environmental Bacteriophages**. *Sci Rep* 2016, **6**:37956.
- 248 13. Høyland-Kroghsbo NM, Maerkedahl RB, Svenningsen SL: **A quorum-sensing-induced**  
249 **bacteriophage defense mechanism**. *mBio* 2013, **4**:e00362-00312.
- 250 14. Tan D, Svenningsen SL, Middelboe M: **Quorum Sensing Determines the Choice of Antiphage**  
251 **Defense Strategy in *Vibrio anguillarum***. *mBio* 2015, **6**:e00627.
- 252 15. Høyland-Kroghsbo NM, Paczkowski J, Mukherjee S, Broniewski J, Westra E, Bondy-Denomy J,  
253 Bassler BL: **Quorum sensing controls the *Pseudomonas aeruginosa* CRISPR-Cas adaptive**  
254 **immune system**. *Proc Natl Acad Sci U S A* 2017, **114**:131-135.
- 255 16. Patterson AG, Jackson SA, Taylor C, Evans GB, Salmond GPC, Przybilski R, Staals RHJ, Fineran PC:  
256 **Quorum Sensing Controls Adaptive Immunity through the Regulation of Multiple CRISPR-Cas**  
257 **Systems**. *Mol Cell* 2016, **64**:1102-1108.
- 258 17. Hazan R, Engelberg-Kulka H: ***Escherichia coli* mazEF-mediated cell death as a defense mechanism**  
259 **that inhibits the spread of phage P1**. *Mol Genet Genomics* 2004, **272**:227-234.
- 260 18. Kumar S, Kolodkin-Gal I, Engelberg-Kulka H: **Novel quorum-sensing peptides mediating**  
261 **interspecies bacterial cell death**. *mBio* 2013, **4**:e00314-00313.
- 262 19. Ding Y, Zhang D, Zhao X, Tan W, Zheng X, Zhang Q, Ji X, Wei Y: **Autoinducer-2-mediated quorum-**  
263 **sensing system resists T4 phage infection in *Escherichia coli***. *J Basic Microbiol* 2021, **61**:1113-  
264 1123.
- 265 20. Goo E, An JH, Kang Y, Hwang I: **Control of bacterial metabolism by quorum sensing**. *Trends*  
266 *Microbiol* 2015, **23**:567-576.
- 267 21. Laganenka L, Sander T, Lagonenko A, Chen Y, Link H, Sourjik V: **Quorum Sensing and Metabolic**  
268 **State of the Host Control Lysogeny-Lysis Switch of Bacteriophage T1**. *MBio* 2019, **10**.
- 269 22. Silpe JE, Bassler BL: **A Host-Produced Quorum-Sensing Autoinducer Controls a Phage Lysis-**  
270 **Lysogeny Decision**. *Cell* 2019, **176**:268-280.e213.

- 271 23. Shah M, Taylor VL, Bona D, Tsao Y, Stanley SY, Pimentel-Elardo SM, McCallum M, Bondy-Denomy  
272 J, Howell PL, Nodwell JR, et al.: **A phage-encoded anti-activator inhibits quorum sensing in**  
273 ***Pseudomonas aeruginosa***. *Mol Cell* 2021, **81**:571-583.e576.
- 274 24. Tyc O, Song C, Dickschat JS, Vos M, Garbeva P: **The Ecological Role of Volatile and Soluble**  
275 **Secondary Metabolites Produced by Soil Bacteria**. *Trends Microbiol* 2017, **25**:280-292.
- 276 25. Hardy A, Kever L, Frunzke J: **Antiphage small molecules produced by bacteria - beyond protein-**  
277 **mediated defenses**. *Trends Microbiol* 2022.
- 278 26. Kronheim S, Daniel-Ivad M, Duan Z, Hwang S, Wong AI, Mantel I, Nodwell JR, Maxwell KL: **A**  
279 **chemical defence against phage infection**. *Nature* 2018, **564**:283-286.
- 280 27. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: **Anthracyclines: molecular advances and**  
281 **pharmacologic developments in antitumor activity and cardiotoxicity**. *Pharmacol Rev* 2004,  
282 **56**:185-229.
- 283 28. Kever L, Hardy A, Luthe T, Hünnefeld M, Gätgens C, Milke L, Wiechert J, Wittmann J, Moraru C,  
284 Marienhagen J, et al.: **Aminoglycoside Antibiotics Inhibit Phage Infection by Blocking an Early**  
285 **Step of the Infection Cycle**. *mBio* 2022, **13**:e0078322.
- 286 29. Krause KM, Serio AW, Kane TR, Connolly LE: **Aminoglycosides: An Overview**. *Cold Spring Harb*  
287 *Perspect Med* 2016, **6**.
- 288 30. Hopwood DA: **How do antibiotic-producing bacteria ensure their self-resistance before antibiotic**  
289 **biosynthesis incapacitates them?** *Mol Microbiol* 2007, **63**:937-940.
- 290 31. Tenconi E, Rigali S: **Self-resistance mechanisms to DNA-damaging antitumor antibiotics in**  
291 **actinobacteria**. *Curr Opin Microbiol* 2018, **45**:100-108.
- 292 32. Kever L, Hardy A, Luthe T, Hünnefeld M, Gätgens C, Milke L, Wiechert J, Wittmann J, Moraru C,  
293 Marienhagen J, et al.: **Aminoglycoside antibiotics inhibit phage infection by blocking an early**  
294 **step of the phage infection cycle**. *bioRxiv preprint* 2021,  
295 <https://doi.org/10.1101/2021.05.02.442312>.
- 296 33. Dimitriu T, Kurilovich E, Łapińska U, Severinov K, Pagliara S, Szczelkun MD, Westra ER:  
297 **Bacteriostatic antibiotics promote CRISPR-Cas adaptive immunity by enabling increased**  
298 **spacer acquisition**. *Cell Host Microbe* 2022, **30**:31-40.e35.
- 299 34. Pons JP, Dimitriu T, Westra ER, van Houte S: **Antibiotics that affect translation can antagonize**  
300 **phage infectivity by interfering with the deployment of counter-defences**. *bioRxiv preprint*  
301 2022, [doi.org/10.1101/2022.09.07.506948](https://doi.org/10.1101/2022.09.07.506948).
- 302 35. Toyofuku M, Nomura N, Eberl L: **Types and origins of bacterial membrane vesicles**. *Nat Rev*  
303 *Microbiol* 2019, **17**:13-24.
- 304 36. Brown L, Wolf JM, Prados-Rosales R, Casadevall A: **Through the wall: extracellular vesicles in**  
305 **Gram-positive bacteria, mycobacteria and fungi**. *Nat Rev Microbiol* 2015, **13**:620-630.
- 306 37. Bayer MH, Costello GP, Bayer ME: **Isolation and partial characterization of membrane vesicles**  
307 **carrying markers of the membrane adhesion sites**. *J Bacteriol* 1982, **149**:758-767.
- 308 38. Beerens D, Franch-Arroyo S, Sullivan TJ, Goosmann C, Brinkmann V, Charpentier E: **Survival**  
309 **Strategies of *Streptococcus pyogenes* in Response to Phage Infection**. *Viruses* 2021, **13**.
- 310 39. Manning AJ, Kuehn MJ: **Contribution of bacterial outer membrane vesicles to innate bacterial**  
311 **defense**. *BMC Microbiol* 2011, **11**:258.
- 312 40. Reyes-Robles T, Dillard RS, Cairns LS, Silva-Valenzuela CA, Housman M, Ali A, Wright ER, Camilli A:  
313 ***Vibrio cholerae* Outer Membrane Vesicles Inhibit Bacteriophage Infection**. *J Bacteriol* 2018,  
314 **200**.
- 315 41. Stephan MS, Broecker NK, Saragliadis A, Roos N, Linke D, Barbirz S: **In vitro Analysis of O-Antigen-**  
316 **Specific Bacteriophage P22 Inactivation by *Salmonella* Outer Membrane Vesicles**. *Front*  
317 *Microbiol* 2020, **11**:510638.
- 318 42. Mandal PK, Ballerin G, Nolan LM, Petty NK, Whitchurch CB: **Bacteriophage infection of *Escherichia***  
319 ***coli* leads to the formation of membrane vesicles via both explosive cell lysis and membrane**  
320 **blebbing**. *Microbiology (Reading)* 2021, **167**.

- 321 43. Yasuda M, Yamamoto T, Nagakubo T, Morinaga K, Obana N, Nomura N, Toyofuku M: **Phage Genes**  
322 **Induce Quorum Sensing Signal Release through Membrane Vesicle Formation.** *Microbes*  
323 *Environ* 2022, **37**.
- 324 44. Toyofuku M, Morinaga K, Hashimoto Y, Uhl J, Shimamura H, Inaba H, Schmitt-Kopplin P, Eberl L,  
325 Nomura N: **Membrane vesicle-mediated bacterial communication.** *Isme j* 2017, **11**:1504-  
326 1509.
- 327 45. Dragoš A, Kovács Á T: **The Peculiar Functions of the Bacterial Extracellular Matrix.** *Trends Microbiol*  
328 2017, **25**:257-266.
- 329 46. Flemming HC, van Hullebusch ED, Neu TR, Nielsen PH, Seviour T, Stoodley P, Wingender J, Wuertz  
330 S: **The biofilm matrix: multitasking in a shared space.** *Nat Rev Microbiol* 2022.
- 331 47. Flemming HC, Wuertz S: **Bacteria and archaea on Earth and their abundance in biofilms.** *Nat Rev*  
332 *Microbiol* 2019, **17**:247-260.
- 333 48. Taylor BP, Penington CJ, Weitz JS: **Emergence of increased frequency and severity of multiple**  
334 **infections by viruses due to spatial clustering of hosts.** *Phys Biol* 2017, **13**:066014.
- 335 49. Ciofu O, Moser C, Jensen P, Høiby N: **Tolerance and resistance of microbial biofilms.** *Nat Rev*  
336 *Microbiol* 2022, **20**:621-635.
- 337 50. Bryan D, El-Shibiny A, Hobbs Z, Porter J, Kutter EM: **Bacteriophage T4 Infection of Stationary Phase**  
338 **E. coli: Life after Log from a Phage Perspective.** *Front Microbiol* 2016, **7**:1391.
- 339 51. Łoś M, Golec P, Łoś JM, Węglewska-Jurkiewicz A, Czyz A, Węgrzyn A, Węgrzyn G, Neubauer P:  
340 **Effective inhibition of lytic development of bacteriophages lambda, P1 and T4 by starvation**  
341 **of their host, Escherichia coli.** *BMC Biotechnol* 2007, **7**:13.
- 342 52. Melo LDR, França A, Brandão A, Sillankorva S, Cerca N, Azeredo J: **Assessment of Sep1virus**  
343 **interaction with stationary cultures by transcriptional and flow cytometry studies.** *FEMS*  
344 *Microbiol Ecol* 2018, **94**.
- 345 53. Tkhilaishvili T, Lombardi L, Klatt AB, Trampuz A, Di Luca M: **Bacteriophage Sb-1 enhances antibiotic**  
346 **activity against biofilm, degrades exopolysaccharide matrix and targets persisters of**  
347 **Staphylococcus aureus.** *Int J Antimicrob Agents* 2018, **52**:842-853.
- 348 54. Abedon ST: **Bacteriophage exploitation of bacterial biofilms: phage preference for less mature**  
349 **targets?** *FEMS Microbiol Lett* 2016, **363**.
- 350 55. Abedon ST: **Phage "delay" towards enhancing bacterial escape from biofilms: a more**  
351 **comprehensive way of viewing resistance to bacteriophages.** *AIMS Microbiol* 2017, **3**:186-  
352 226.
- 353 56. Bull JJ, Christensen KA, Scott C, Jack BR, Crandall CJ, Krone SM: **Phage-Bacterial Dynamics with**  
354 **Spatial Structure: Self Organization around Phage Sinks Can Promote Increased Cell**  
355 **Densities.** *Antibiotics (Basel)* 2018, **7**.
- 356 57. Hewson I, Fuhrman JA: **Viriobenthos production and virioplankton sorptive scavenging by**  
357 **suspended sediment particles in coastal and pelagic waters.** *Microb Ecol* 2003, **46**:337-347.
- 358 58. Rabinovitch A, Aviram I, Zaritsky A: **Bacterial debris-an ecological mechanism for coexistence of**  
359 **bacteria and their viruses.** *J Theor Biol* 2003, **224**:377-383.
- 360 59. Simmons EL, Bond MC, Koskella B, Drescher K, Bucci V, Nadell CD: **Biofilm Structure Promotes**  
361 **Coexistence of Phage-Resistant and Phage-Susceptible Bacteria.** *mSystems* 2020, **5**.
- 362 60. Yin J, McCaskill JS: **Replication of viruses in a growing plaque: a reaction-diffusion model.** *Biophys*  
363 *J* 1992, **61**:1540-1549.
- 364 61. Simmons M, Drescher K, Nadell CD, Bucci V: **Phage mobility is a core determinant of phage-**  
365 **bacteria coexistence in biofilms.** *Isme j* 2018, **12**:531-543.
- 366 62. Briandet R, Lacroix-Gueu P, Renault M, Lecart S, Meylheuc T, Bidnenko E, Steenkeste K, Bellon-  
367 Fontaine MN, Fontaine-Aupart MP: **Fluorescence correlation spectroscopy to study diffusion**  
368 **and reaction of bacteriophages inside biofilms.** *Appl Environ Microbiol* 2008, **74**:2135-2143.
- 369 63. Doolittle MM, Cooney JJ, Caldwell DE: **Tracing the interaction of bacteriophage with bacterial**  
370 **biofilms using fluorescent and chromogenic probes.** *J Ind Microbiol* 1996, **16**:331-341.

- 371 64. Lacroix-Gueu P, Briandet R, Lévêque-Fort S, Bellon-Fontaine MN, Fontaine-Aupart MP: **In situ**  
372 **measurements of viral particles diffusion inside mucoid biofilms.** *C R Biol* 2005, **328**:1065-  
373 1072.
- 374 65. Melo LDR, Pinto G, Oliveira F, Vilas-Boas D, Almeida C, Sillankorva S, Cerca N, Azeredo J: **The**  
375 **Protective Effect of Staphylococcus epidermidis Biofilm Matrix against Phage Predation.**  
376 *Viruses* 2020, **12**.
- 377 66. González S, Fernández L, Gutiérrez D, Campelo AB, Rodríguez A, García P: **Analysis of Different**  
378 **Parameters Affecting Diffusion, Propagation and Survival of Staphylophages in Bacterial**  
379 **Biofilms.** *Front Microbiol* 2018, **9**:2348.
- 380 67. Dunsing V, Irmischer T, Barbirz S, Chiantia S: **Purely Polysaccharide-Based Biofilm Matrix Provides**  
381 **Size-Selective Diffusion Barriers for Nanoparticles and Bacteriophages.** *Biomacromolecules*  
382 2019, **20**:3842-3854.
- 383 68. Vidakovic L, Singh PK, Hartmann R, Nadell CD, Drescher K: **Dynamic biofilm architecture confers**  
384 **individual and collective mechanisms of viral protection.** *Nat Microbiol* 2018, **3**:26-31.
- 385 69. Chaudhry W, Lee E, Worthy A, Weiss Z, Grabowicz M, Vega N, Levin B: **Mucoidy, a general**  
386 **mechanism for maintaining lytic phage in populations of bacteria.** *FEMS Microbiol Ecol* 2020,  
387 **96**.
- 388 70. Darch SE, Kragh KN, Abbott EA, Bjarnsholt T, Bull JJ, Whiteley M: **Phage Inhibit Pathogen**  
389 **Dissemination by Targeting Bacterial Migrants in a Chronic Infection Model.** *mBio* 2017, **8**.
- 390 71. Pires DP, Melo LDR, Azeredo J: **Understanding the Complex Phage-Host Interactions in Biofilm**  
391 **Communities.** *Annu Rev Virol* 2021, **8**:73-94.
- 392 72. Hansen MF, Svenningsen SL, Røder HL, Middelboe M, Burmølle M: **Big Impact of the Tiny:**  
393 **Bacteriophage-Bacteria Interactions in Biofilms.** *Trends Microbiol* 2019, **27**:739-752.
- 394 73. Tesson F, Bernheim A: **Synergy and regulation of antiphage systems: toward the existence of a**  
395 **bacterial immune system?** *Curr Opin Microbiol* 2022, **71**:102238.
- 396 74. Maguin P, Varble A, Modell JW, Marraffini LA: **Cleavage of viral DNA by restriction endonucleases**  
397 **stimulates the type II CRISPR-Cas immune response.** *Mol Cell* 2022, **82**:907-919.e907.
- 398 75. Dal Co A, van Vliet S, Kiviet DJ, Schlegel S, Ackermann M: **Short-range interactions govern the**  
399 **dynamics and functions of microbial communities.** *Nat Ecol Evol* 2020, **4**:366-375.
- 400 76. van Gestel J, Bareia T, Tenenbaum B, Dal Co A, Guler P, Aframian N, Puyesky S, Grinberg I, D'Souza  
401 GG, Erez Z, et al.: **Short-range quorum sensing controls horizontal gene transfer at micron**  
402 **scale in bacterial communities.** *Nat Commun* 2021, **12**:2324.
- 403 77. Zhang Z, Du C, de Barsey F, Liem M, Liakopoulos A, van Wezel GP, Choi YH, Claessen D, Rozen DE:  
404 **Antibiotic production in Streptomyces is organized by a division of labor through terminal**  
405 **genomic differentiation.** *Sci Adv* 2020, **6**:eaay5781.
- 406 78. Zhang Z, Shitut S, Claushuis B, Claessen D, Rozen DE: **Mutational meltdown of putative microbial**  
407 **altruists in Streptomyces coelicolor colonies.** *Nat Commun* 2022, **13**:2266.

408

#### 409 **Annotations**

410 (\*) 23. Shah M, Taylor VL, Bona D, Tsao Y, Stanley SY, Pimentel-Elardo SM, McCallum M, Bondy-  
411 Denomy J, Howell PL, Nodwell JR, et al.: A phage-encoded anti-activator inhibits quorum sensing in  
412 *Pseudomonas aeruginosa*. *Mol Cell* 2021, **81**:571-583.e576.

413 **This study provides a compelling example of how phages can disrupt key biological pathways of the**  
414 **host via production of quorum-sensing anti-activator proteins. Aqs1 produced by Pseudomonas**  
415 **phage DMS3 was shown to inhibit LasR, the master regulator of quorum sensing and to block**  
416 **superinfection of phages requiring the pilus for infection.**

417

418 (\*\*) 26. Kronheim S, Daniel-Ivad M, Duan Z, Hwang S, Wong AI, Mantel I, Nodwell JR, Maxwell KL: A  
419 chemical defence against phage infection. *Nature* 2018, **564**:283-286.

420 **Definition of the term ‘chemical defense’. Systematic screening of bacterial secondary metabolites**  
421 **and demonstration of the antiphage properties of anthracyclines active against a broad range of**  
422 **phages.**

423 (\*\*) 28. Kever L, Hardy A, Luthe T, Hünnefeld M, Gätgens C, Milke L, Wiechert J, Wittmann J, Moraru  
424 C, Marienhagen J, et al.: Aminoglycoside Antibiotics Inhibit Phage Infection by Blocking an Early Step  
425 of the Infection Cycle. *mBio* 2022, 13:e0078322.


426 **Demonstration of the antiphage properties of aminoglycoside antibiotics. Using strains resistant to**  
427 **the molecule of interest allowed for the appreciation of the antiphage properties. Acetylation of**  
428 **apramycin abolished its antibacterial properties but retained its ability to block phage infection.**

429 (\*) 57. Simmons EL, Bond MC, Koskella B, Drescher K, Bucci V, Nadell CD: Biofilm Structure Promotes  
430 Coexistence of Phage-Resistant and Phage-Susceptible Bacteria. *mSystems* 2020, 5.

431 **This study combines simulations and in vivo work to show how phage-resistant cells can protect**  
432 **clusters of susceptible cells, which promotes the (co)existence of susceptible cells in the presence**  
433 **of phages.**

434

435



436

437 **Figure 1: Bacterial multicellular strategies in antiviral defense.** Protection against phages on a  
 438 multicellular level can be mediated by i) extrusion of outer membrane vesicles sequestering phages,  
 439 which prevents attachment to susceptible cells, ii) quorum sensing-mediated activation of antiphage  
 440 defense systems, iii) biofilm formation and trapping of phages via interaction with components of the  
 441 extracellular matrix, iv) production of antiphage molecules used as chemical defense and v) cellular  
 442 development allowing emergence of transient phage tolerance.